Heidelberg Pharma AG, a clinical
stage company developing innovative Antibody Drug Conjugates (ADCs), will present new
data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, pamlectabart
tismanitin (HDP-101), at the 23rd International Myeloma Society (IMS) Annual Meeting, being
held in Glasgow, Scotland, on 23 to 26 September 2026.
• Existing partnership will be broadened through joint research and development of new Antibody Drug Conjugates (ADCs) involving up to six targets
• Heidelberg Pharma’s pipeline will be expanded with new product candidates
• Both parties to contribute their strength and proprietary technologies, including Heidelberg Pharma’s ADC technology
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial report on the first six months of 2026 (1 December 2025 – 31 May 2026) and reported on the course of business.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.67% and 98.72%) at today’s ordinary virtual Annual General Meeting.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today reported on the first three months of fiscal year 2026 (1 December 2025 – 28 February 2026) and the Group’s financial figures.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announces the change of its Chief Financial Officer. The current Chief Financial Officer of Heidelberg Pharma AG, Mr. Walter Miller, is leaving Heidelberg Pharma AG at his own request upon the expiration of his employment contract to pursue new professional challenges. Mr. Peter Willinger will assume the role of Chief Financial Officer effective 1 May 2026.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the determination of the recommended Phase II dose (RP2D) in its Phase I/IIa study with pamlectabart tismanitin (HDP-101) for the treatment of relapsed or refractory multiple myeloma. Heidelberg Pharma’s Benefit and Risk Assessment team agreed with the recommendation by the study’s Safety Review Committee (SRC), which had conducted a comprehensive review of safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing Phase I/IIa trial.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), will present promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration-resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA, from 17 to 22 April.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial results and Annual Report for fiscal year 2025 (1 December 2024 – 30 November 2025) and its outlook for 2026.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its partner Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) has reached a development milestone under the terms of the license agreement from February 2022. With the dosing of the first patient in a clinical study with HDP-101 (INN: pamlectabart tismanitin) in China, a planned milestone payment to Heidelberg Pharma became due and is being processed. Financial details were not disclosed.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced on 7 March an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, a milestone payment to Heidelberg Pharma became due. Financial details were not disclosed.
The past few months have been turbulent and difficult for Heidelberg Pharma. We have been confronted with events and changes that required swift and decisive action. Today, I am writing to you to explain where we stand – and, above all, why I am deeply convinced that the difficult path we have now embarked upon will be worthwhile.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer, with immediate effect.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma, shows further clinical activity in Cohort 8 at a dose level of 140 µg/kg. These findings are highlighted by observed stringent complete remissions in two patients from Cohort 8.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announced the presentation of new clinical data from its ongoing Phase I/IIa clinical study evaluating its lead Amanitin-based ADC candidate, HDP-101 (INN: pamlectabart tismanitin), at the 16th Annual World ADC Congress, taking place in San Diego, California, from 3 to 6 November 2025.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead Amanitin-based ADC candidate, has been granted Fast Track Designation by the US Food and Drug Administration (FDA).
Heidelberg Pharma AG reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2025 (1 December 2024 – 31 August 2025).
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 21 March 2025, due to current focus and cost-saving measures.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today resolved with the approval of the Supervisory Board to implement extensive cost-saving measures and consequently, to focus all development activities exclusively on lead ADC candidate HDP-101 to extend the Company’s cash reach. This is due to the delay of an expected milestone payment of USD 70 million from the royalty financing agreement with HealthCare Royalty (HCRx), as the payment condition has not yet been met.
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 22nd International Myeloma Society (IMS) Annual Meeting, being held in Toronto, Canada, on 17 to 20 September 2025.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its licensing partner Telix Pharmaceuticals Limited, headquartered in Melbourne, Australia, (ASX: TLX, NASDAQ: TLX; Telix) was informed by the US Food and Drug Administration (FDA) that deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package have been identified.
Heidelberg Pharma AG published today its financial report on the first six months of 2025 (1 December 2024 – 31 May 2025) and reported about the course of business.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL).
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.03% and 99.99%) at today’s ordinary virtual Annual General Meeting.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting new clinical data on its lead Amanitin-based ADC candidate, HDP-101 at the 30th European Hematology Association (EHA) Congress, taking place in Milan, Italy, from 12 – 15 June 2025.
Heidelberg Pharma AG today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April.
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook for 2025.
Heidelberg Pharma AG, a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed an amendment to the royalty financing agreement entered into in March 2024.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, California, USA.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November.
Heidelberg Pharma AG reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2024 (1 December 2023 – 31 August 2024).
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data from its lead Amanitin-based ADC candidate, HDP-101, were presented at the International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil on 27 September 2024.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 18 June 2024 downwards on the cost side.
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 21st International Myeloma Society (IMS) Annual Meeting, being held in Rio De Janeiro, Brazil on 25 to 28 September 2024.
Heidelberg Pharma AG announced that the company’s shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday’s ordinary virtual Annual General Meeting:
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 25 March 2024.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024.
Heidelberg Pharma AG today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2023 (1 December 2022 – 30 November 2023) and its outlook for 2024.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it will be advancing into an expanded Cohort 6 dose escalation following submission of a protocol amendment to the US Food and Drug Administration (FDA) for its Phase I/IIa study with lead ATAC candidate HDP-101 for the treatment of multiple myeloma.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American Association for Cancer Research (AACR) Annual Meeting, being held in San Diego, California on the 5 – 10 April 2024.
Heidelberg Pharma AG, a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement. Formal closing conditions that are expected to be fulfilled in a timely manner must still be met. Heidelberg Pharma is eligible to receive up to USD 115 million from the sale of its future royalties from worldwide sales of Zircaix™ (TLX250-CDx), a microdose radiopharmaceutical Positron Emission Tomography (PET) imaging agent for the diagnosis and follow up of clear cell renal cancer.
